2292-20-8

Usage

Uses

Used in Pharmaceutical Industry:
5,7,8,14-Tetrahydro-3,4,10,11-tetramethoxy-6-methyldibenz[c,g]azecin-13(6H)-one is used as a pharmaceutical compound for its potential therapeutic applications. The alkaloid's unique structure and properties make it a candidate for further research and development in the field of medicine.
Used in Chemical Research:
5,7,8,14-Tetrahydro-3,4,10,11-tetramethoxy-6-methyldibenz[c,g]azecin-13(6H)-one is also used in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique structure and functional groups can be exploited to create new compounds with potential applications in various industries.
Used in Analytical Chemistry:
5,7,8,14-Tetrahydro-3,4,10,11-tetramethoxy-6-methyldibenz[c,g]azecin-13(6H)-one can be used in analytical chemistry for the development of new methods and techniques for the identification and quantification of similar alkaloids in natural sources or synthesized products.
Used in Toxicology Studies:
Due to its occurrence in certain plant species, 5,7,8,14-Tetrahydro-3,4,10,11-tetramethoxy-6-methyldibenz[c,g]azecin-13(6H)-one may be used in toxicology studies to understand its effects on human health and the environment, as well as to develop methods for its detection and quantification in biological samples.
Used in Drug Delivery Systems:
Similar to gallotannin, 5,7,8,14-Tetrahydro-3,4,10,11-tetramethoxy-6-methyldibenz[c,g]azecin-13(6H)-one could potentially be used in drug delivery systems to improve the bioavailability and therapeutic outcomes of other pharmaceutical compounds. Further research would be needed to explore this application.

References

Boit, Flentje., Naturwiss., 47, 180 (1960)Preininger et aZ., PZanta Med., 10, 124 (1962)Mass spectrum: Cross et aZ., Collect. Czech. Chern. Cornrnun., 30, 1335 (1965)Synthesis: Haworth, Koepfli, Perkin., 1. Chern. Soc., 2261 (1927)Giacopello, Deulofeu., Tetrahedron Lett., 2859 (1966)

InChI:InChI=1/C22H27NO5/c1-23-9-8-15-11-20(26-3)21(27-4)12-16(15)18(24)10-14-6-7-19(25-2)22(28-5)17(14)13-23/h6-7,11-12H,8-10,13H2,1-5H3

Upstream product

• 112333-55-8 (+/-)-14-Dihydro-nor-muramin 
• 74059-71-5 7,8-dimethoxy-3-methyl-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one 
• 54370-01-3 1-bromo-2-(chloromethyl)-4,5-dimethoxy-benzene 
• 952196-39-3 12-bromo-7-methyl-2,3,9,10-tetramethoxy-5,6,7,8,13,14-hexahydrodibenz[c,g]azecine-8,14-dione 
• 952196-32-6 11-bromo-2,3,8,9-tetramethoxy-5,6,7,12-tetrahydroindeno[2,1-a][3]benzazepine 
• 952196-37-1 1-(2-bromo-4,5-dimethoxybenzyl)-7,8-dimethoxy-3-methyl-1,2,4,5-tetrahydro-3H-3-benzazepin-2-one 
• 93264-43-8 Dihydromuramin 
• 112333-54-7 13-Hydroxy-3,4,10,11-tetramethoxy-7,8,13,14-tetrahydro-5H-dibenzo[c,g]azecine-6-carbonitrile 

Downstream Products

• 7236-30-8 α-allocryptopine methiodide 

Relevant academic research and scientific papers

On the synthesis of protopine alkaloids

(Chemical Equation Presented) For the synthesis of protopine alkaloids, we studied a reaction sequence based on a ring enlargement of indeno[2,1-a][3] benzazepines by a singlet oxygen oxygenation, followed by conversion of an amide carbonyl group of the resultant 10-membered keto-lactam to a methylene group, which is the last step for completion of the synthesis. The key substances, indeno[2,1-a][3]benzazepines, were prepared by Bischler-Napieralski cyclization of alkoxy-substituted 1-(2-bromobenzyl)-3-benzazepin-2-ones. Steric effects of the substituents in this synthesis were examined.